Beauty Health Q4 2024 Earnings Report
Key Takeaways
BeautyHealth's Q4 2024 revenue was $83.5 million, a 13.8% decrease year-over-year, driven by lower delivery system sales. The company improved its gross margin to 62.7% and adjusted EBITDA reached $9.0 million. Consumable sales grew, and cost-cutting efforts helped offset revenue declines.
Total revenue for Q4 2024 was $83.5 million, down 13.8% year-over-year.
Gross margin improved to 62.7% from 47.2% in Q4 2023.
Net loss was $10.3 million, slightly worse than $9.4 million in Q4 2023.
Adjusted EBITDA increased to $9.0 million, up from $3.4 million last year.
Beauty Health
Beauty Health
Beauty Health Revenue by Segment
Beauty Health Revenue by Geographic Location
Forward Guidance
BeautyHealth expects continued challenges in delivery system sales but aims to stabilize revenue through consumables and cost efficiencies.
Positive Outlook
- Consumables sales expected to continue growing in 2025.
- Gross margin expected to remain strong with further cost optimizations.
- Expansion of partnerships and product innovations planned for 2025.
- Cash position remains strong at $370 million, supporting future investments.
- Active install base grew to 34,735 systems, supporting recurring revenue.
Challenges Ahead
- Delivery system sales expected to remain under pressure in 2025.
- Macroeconomic uncertainties could impact consumer spending in aesthetics.
- Increased competition in the skincare and beauty device market.
- Transition of China operations from direct sales to distributor model may cause short-term disruptions.
- Projected adjusted EBITDA for Q1 2025 in negative territory (-$6M to -$4M).
Revenue & Expenses
Visualization of income flow from segment revenue to net income